



Hepatitis C Drug Therapy Product Selection Grid

Mavyret™ is the preferred Hepatitis C product. Documentation on reason or contraindication must be provided when requesting other products.

Drug Therapy	Cirrhosis	G1a		G1b		G2		G3		G4		G5		G6	
		TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE
Mavyret™	No	8w	8w ¹ , 12w ^{4,9} , 16w ^{8z}	8w	8w ¹ , 12w ^{4,9} , 16w ^{8z}	8w	8w ¹ , 12w ²	8w	16w ¹	8w	8w ¹	8w	8w ¹	8w	8w ¹
	No & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]
	Comp	12w	12w ^{1,4,9} , 16w ^{8z}	12w	12w ^{1,4,9} , 16w ^{8z}	12w	12w ^{1,2}	12w	16w ¹	12w	12w ¹	12w	12w ¹	12w	12w ¹
	Comp & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]
Zepatier™	No	12w ^t	12w ^{t1}	12w	12w ¹					12w	12w ^{1a}				
	Comp	12w ^t	12w ^{t1}	12w	12w ¹					12w	12w ^{1a}				
Zepatier™ + RBV	No	16w ^t	12-16w ^{p4} , 16w ^{t1}		12w ⁴						16w ^{1b}				
	Comp	16w ^t	12-16w ^{p4} , 16w ^{t1}		12w ⁴						16w ^{1b}				
Zepatier™ + Sovaldi®	No							12w							
	Comp							12w	12w ¹						
Eplclusa®	No	12w	12w ⁵	12w	12w ^{5,9}	12w	12w ^{2,5}	12w	12w ^{5~}	12w	12w ⁵	12w	12w ⁵	12w	12w ⁵
	Comp	12w	12w ⁵	12w	12w ^{5,9}	12w	12w ^{2,5}	12w [~]	12w ⁵	12w	12w ⁵	12w	12w ⁵	12w	12w ⁵
	Decomp	24w		24w		24w		24w		24w		24w		24w	
Eplclusa® + RBV	No								12w ^{1~}						
	Comp							12w [~]	12w ¹						
	Comp & Post Transplant [^]					12w [^]	12w [^]	12w [^]	12w [^]						
	Decomp	12w	12w ⁵ , 24w ¹⁰	12w	12w ⁵ , 24w ¹⁰	12w	12w ⁵ , 24w ¹⁰	12w	12w ⁵ , 24w ¹⁰	12w	12w ⁵ , 24w ¹⁰	12w	12w ⁵ , 24w ¹⁰	12w	12w ⁵ , 24w ¹⁰
	Decomp & Post Transplant [^]					12w [^]	12w [^]	12w [^]	12w [^]						



Hepatitis C Drug Therapy Product Selection Grid

Drug Therapy	Cirrhosis	G1a		G1b		G2		G3		G4		G5		G6	
		TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE
Vosevi®	No		12w ^{8,9}		12w ⁸		12w ⁸		12w ^{1#,6,9}		12w ⁶		12w ⁶		12w ⁶
	Comp		12w ^{8,9}		12w ⁸		12w ⁸	12w [#]	12w ^{1,7,9}		12w ⁶		12w ⁶		12w ⁶
Vosevi® + RBV	No														
	Comp								12w ⁸						
Viekira Pak™/XR™	No			12w	12w ¹										
	Comp			12w	12w ¹										
Viekira Pak™/XR™ + RBV	No	12w	12w ¹												
	No & Post Transplant [^]	24w [^]		24w [^]											
	Comp	24w	24w ¹												
Technivie™+ RBV	No									12w	12w ¹				
	Comp									12w	12w ¹				
Harvoni®	No	12w	12w ⁵	12w	12w ⁵					12w	12w ¹	12w	12w ¹	12w	12w ¹
	No & low HCV RNA [*]	8w [*]		8w [*]											
	Comp	12w	24w ⁵	12w	24w ⁵					12w	12w ¹	12w	12w ¹	12w	12w ¹
	Decomp	24w		24w						24w		24w		24w	
Harvoni® + RBV	No		12w ^{9x}		12w ^{9x}										
	No & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]					12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]
	Comp		12w ⁵		12w ⁵						12w ¹				
	Comp & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]					12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]
	Decomp	12w	24w ¹¹	12w	24w ¹¹					12w	24w ¹¹	12w	24w ¹¹	12w	24w ¹¹
	Decomp & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]					12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]
Sovaldi® + RBV	No					12w	12w ¹	24w ¹	24w ¹						
	Comp					12w	12w ¹	24w ¹	24w ¹						



Hepatitis C Drug Therapy Product Selection Grid

Drug Therapy	Cirrhosis	G1a		G1b		G2		G3		G4		G5		G6	
		TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE
Olysio® + Sovaldi®	No	12w	12w ¹	12w	12w ¹										
	No & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]					12w [^]	12w [^]				
	Comp	24w ⁿ	24w ⁿ¹	24w	24w ¹										
	Comp & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]					12w [^]	12w [^]				
Daklinza® + Sovaldi®	No	12w	12w ¹	12w	12w ¹	12w	12w ¹	12w	12w ¹						
	Comp	12w		12w		16-24w	16-24w ¹	24w [~]							
	Decomp	24w		24w		24w		24w		24w					
Daklinza® + Sovaldi® + RBV	No														
	No & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]
	Comp							12w, 24w [~]							
	Comp & Post Transplant [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]	12w [^]
	Decomp	12w		12w		12w		12w		12w					
Decomp & Post Transplant [^]					12w [^]	12w [^]	12w [^]	12w [^]							



Hepatitis C Drug Therapy Product Selection Grid

[†]For genotype 1a, Zepatier™ should be given alone for 12 weeks in patients without, or with ribavirin for 16 weeks in patients with, NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93.

[‡]Patients who have NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93 should have treatment extended to 16 weeks.

[§]Only for patients who have tested negative for the Q80K variant.

[¶]Except in patients who have failed simeprevir.

^{**}Except in patients who have failed NS3/4 protease inhibitor inclusive direct-acting antiviral combination regimens.

^{††}Harvoni® for 8 weeks may be considered in G1 treatment-naïve patients without cirrhosis who are non-black, HIV-uninfected, and have a pre-treatment HCV RNA < 6 million IU/ml.

^{†††}RAS testing for Y93H is recommended. If present, ribavirin should be added to the regimen.

^{††††}An alternative regimen for patients when Y93H is present.

^{†††††}For patients who develop HCV infection post-liver transplantation.

^{††††††}For patients who have failed pegIFN/RBV.

^{†††††††}For patients who experienced virologic relapse after prior pegIFN/RBV therapy.

^{††††††††}For patients who experienced on-treatment virologic failure while on prior pegIFN/

^{†††††††††}For patients who have failed sofosbuvir + RBV.

^{††††††††††}For patients who have failed sofosbuvir + RBV +/- pegIFN.

^{†††††††††††}For patients who have failed a NS3 protease inhibitor + pegIFN/RBV.

^{††††††††††††}For patients who have failed pegIFN/RBV +/- a NS3 protease inhibitor.

^{†††††††††††††}For patients who have failed direct-acting antiviral (including NS5A Inhibitor).

^{††††††††††††††}For patients who have failed direct-acting antiviral (not including NS5A Inhibitor).

^{†††††††††††††††}For patients who have failed a NS5A inhibitor.

^{††††††††††††††††}For patients who have failed a non-NS5A inhibitor, sofosbuvir-containing regimen.

^{†††††††††††††††††}For patients who failed a sofosbuvir- or NS5A-containing regimen.

^{††††††††††††††††††}For patients who failed a sofosbuvir-based treatment only.

Key	
TN	Treatment-naïve
TE	Treatment-experienced
Comp	Compensated
Decomp	Decompensated
RBV	Ribavirin
pegIFN	Peginterferon
	Preferred First Line Therapy

References:

- <http://hcvguidelines.org/full-report-view>.
- http://packageinserts.bms.com/pi/pi_daklinza.pdf.
- http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf.
- http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf.
- http://www.rxabbvie.com/pdf/mavyret_pi.pdf.
- <http://www.olyzio.com/shared/product/olyzio/prescribing-information.pdf>.
- http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf.
- http://www.rxabbvie.com/pdf/technivie_pi.pdf.
- http://www.rxabbvie.com/pdf/viekirapak_pi.pdf.
- http://www.rxabbvie.com/pdf/viekiraxr_pi.pdf.
- http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/vosevi/vosevi_pi.pdf.
- http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf.
- https://pdf.hres.ca/dpd_pm/00039964.PDF.